UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2005
THERMOGENESIS CORP.
(Exact name of registrant as specified in its charter)
Delaware 0-16375 94-3018487
--------- -------- ----------
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
2711 Citrus Road
Rancho Cordova, California 95742
(Address and telephone number of principal executive offices) (Zip Code)
(916) 858-5100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Section 1 - Registrant's Business and Operations
------------------------------------------------
Item 1.01 Entry into a Material Definitive Agreement
On November 7, 2005, ThermoGenesis Corp. ("TGC") entered into an OEM Supply
Agreement (the "Agreement") with Medtronic, Inc. ("MDT"). Under the terms of the
Agreement, TGC will supply its Thrombin Processing Device to MDT for use in and
sale with the MDT Magellan Product throughout the world. The Agreement has a
term of five (5) years. TGC's proprietary Thrombin Processing Device is a
stand-alone disposable which produces autologous thrombin from plasma which is
used for topical hemostasis and releasing growth factors from platelets
(platelet gel). MDT's Magellan Product is used for the production of platelet
gel by combining the concentrated platelets produced with a separate thrombin
source to create a platelet gel used to accelerate wound healing in surgical
applications.
The agreement furthers TGC's strategy to develop strategic relationships
with established companies that have the ability to expand the distribution
channels for its products and for product line extensions.
For more information, see the Agreement attached as Exhibit 10 and the
Press Release attached as Exhibit 99.1.
Section 9 - Financial Statements and Exhibits
---------------------------------------------
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Exhibit Description
----------- -------------------
10 OEM Supply Agreement between ThermoGenesis
Corp. and Medtronic Inc. dated November 7, 2005
99.1 Press Release dated November 8, 2005.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THERMOGENESIS CORP.,
a Delaware Corporation
Dated: November 10, 2005 /s/ Matthew Plavan
--------------------------------------------
Matthew Plavan,
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Exhibit Description
----------- -------------------
10 OEM Supply Agreement between ThermoGenesis
Corp. and Medtronic Inc. dated November 7, 2005
99.1 Press Release dated November 8, 2005.